Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

This publication has 24 references indexed in Scilit:

• The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects
  Journal of Clinical Endocrinology & Metabolism, 1992
• Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 1990
• POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS
  Clinical Endocrinology, 1990
• A phase I trial of CGS 16949a. A new aromatase inhibitor
  Cancer, 1990
• Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal
  Journal of Steroid Biochemistry, 1989
• Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women
  Journal of Steroid Biochemistry, 1989
• In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A
  Steroids, 1987
• ENDOCRINE EFFECTS OF LOW DOSE AMINOGLUTETHIMIDE AS AN AROMATASE INHIBITOR IN THE TREATMENT OF BREAST CANCER
  Clinical Endocrinology, 1985
• LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER
  The Lancet, 1984
• Aminoglutethimide dose and hormone suppression in advanced breast cancer
  European Journal of Cancer and Clinical Oncology, 1983